The successful delivery of cell and gene therapies requires a well-designed, streamlined supply chain. To further support companies developing autologous and allogeneic cell therapies, Be The Match BioTherapies® and Cryoport, the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, have partnered to deliver end-to-end supply chain services.
“This new partnership will leverage the strengths of Cryoport and Be The Match BioTherapies to provide a unique set of standardized end-to-end workflow and logistics management services — beginning with cell harvest at apheresis centers, continuing through the supply chain, and ending with outcomes tracking — for the cell and gene therapy industry,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies, in a press release announcing the collaboration.
In addition to integrating Cryoport’s expertise in temperature-controlled logistics with the expertise of Be The Match BioTherapies in apheresis center onboarding and management, case management and logistics, clinical research and outcomes data collection and analysis, a key component is the integration of software platforms. Through Be The Match BioTherapies’ MatchSource® cell therapy supply chain software and Cryoport’s Cryoportal™ Logistics Management Platform, users have access to a platform that manages more cell therapy products than any other solution in the marketplace, enabling cell and gene therapy companies to more rapidly discover, develop and deliver next-generation therapies.